Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.820
+0.440 (10.05%)
Jun 29, 2026, 3:14 PM EDT - Market open
Company Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.
Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated
| Country | United States |
| Founded | 2016 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Krishna Vaddi |
Contact Details
Address: 175 Innovation Boulevard Wilmington, Delaware 19805 United States | |
| Phone | 302 467 1280 |
| Website | preludetx.com |
Stock Details
| Ticker Symbol | PRLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001678660 |
| CUSIP Number | 74065P101 |
| ISIN Number | US74065P1012 |
| Employer ID | 81-1384762 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, Chief Executive Officer and Director |
| Bryant David Lim J.D. | Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Aimee Crombie Ph.D. | Senior Vice President and Head of Strategic Planning and Operations |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations |
| Robert A. Doody Jr. | Senior Vice President of Investor Relations |
| Michele Porreca M.B.A. | Chief People Officer |
| Dr. Andrew P. Combs Ph.D. | Executive Vice President and Chief Chemistry Officer |
| Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine |
| Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2026 | SCHEDULE 13G | Filing |
| Apr 23, 2026 | SCHEDULE 13D/A | Filing |
| Apr 22, 2026 | SCHEDULE 13D/A | Filing |
| Apr 21, 2026 | 8-K | Current Report |